The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revolo Biotherapeutics’ ‘1104 to treat eosinophilic esophagitis (EoE). EoE is a chronic, allergic inflammatory disease that is characterised by the accumulation of eosinophils in the lining of the esophagus. Inflammation caused by immune cells such as T cells and mast cells results […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!